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Abstract
This paper investigates statistical reproducibility of the t-test. We formulate reproducibility as a
predictive inference problem and apply the nonparametric predictive inference (NPI) method. Within
our research framework, statistical reproducibility provides inference on the probability that the same
test outcome would be reached, if the test were repeated under identical conditions. We present an
NPI algorithm to calculate the reproducibility of the t-test and then use simulations to explore the
reproducibility both under the null and alternative hypotheses. We then apply NPI reproducibility
to a real life scenario of a preclinical experiment, which involves multiple pairwise comparisons of
test groups, where different groups are given a different concentration of a drug. The aim of the
experiment is to decide the concentration of the drug which is most effective. In both simulations and
the application scenario, we study the relationship between reproducibility and two test statistics, the
Cohen’s d and the p-value. We also compare the reproducibility of the t-test with the reproducibility of
the Wilcoxon Mann-Whitney test. Finally, we examine reproducibility for the final decision of choosing
a particular dose in the multiple pairwise comparisons scenario. This paper presents advances on
the topic of test reproducibility with relevance for tests used in pharmaceutical research.
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1 Introduction
Reproducibility of tests is a complex issue, which is of importance in pharmaceutical research
and development. Lack of reproducibility contributes to the high failure rate in the drug discovery
process, increasing costs and decreasing efficiency.1–5 There are many factors which may lead to
poor reproducibility, these include wrong or unsuitable statistical analysis of results or inadequate
sample sizes4, and also poor documentation and inappropriate models.5 This paper focuses only on
the variability of statistical methods, which exists due to variability of data, not on further aspects
of reproducibility. By its nature, it is attractive to consider reproducibility as a predictive inference
problem.6,7 Predictive inference is about predicting future observations based on existing data. Assume
that a test has been performed, and a test outcome, whether or not to reject the null hypothesis, has been
reached. We define statistical reproducibility as the probability for the event that, if the test were repeated
under identical circumstances and with the same sample size, the same test outcome would be reached.
Research on statistical reproducibility has been gaining importance for the past three decades. The first
insights related to the topic of this paper were provided by Goodman,8 who highlighted a misconception
regarding the p-value. He questioned the claim that a small p-value increases the credibility of the test
result and argued that the replication probability may be smaller than expected. Although Goodman used
the term replication probability rather than reproducibility probability, his definition is very similar to the
definition of reproducibility adopted in this paper. He defined it as the probability of observing another
statistically significant result in the same direction as the first one, if an experiment was repeated under
identical conditions and with the same sample size. Senn9 agreed with Goodman that the p-value and
replication probability are different measures and that inconsistency between test results from individual
studies may be expected. However, he disagreed with Goodman’s claim that the p-value overstates the
evidence against the null hypothesis.8 Senn pointed out that we should recognise a link between the p-
values and replication probability. In this paper we build further upon Goodman’s and Senn’s discussion
and we provide more insights into statistical reproducibility.
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In the literature, several other approaches to reproducibility probability have been presented. For
example, De Capitani and De Martini10–12 consider the estimated power approach.13 They equate the
reproducibility probability to the true power of a statistical test and they argue that “its estimation
provides useful information to evaluate the stability of statistical test results”.12 They adopt Goodman’s
definition of reproducibility probability, i.e. the probability of obtaining the same test result in a second,
identical experiment, but they consider it as an estimation problem instead of a prediction problem.
Furthermore, they only consider reproducibility in case the null hypothesis is rejected in the test, while
we provide predictive inference for reproducibility both if the null hypothesis is rejected or not rejected.
In this paper, we use the nonparametric predictive inference (NPI) framework for inference on
reproducibility. NPI is a frequentist statistical approach, based on only few assumptions, and focused
on future observations, which makes it a suitable methodology for inference on reproducibility. NPI has
been applied in many areas, for example, in finance,14 system reliability,15 operations research16 and
receiver operating characteristic (ROC) analysis.17
The first application of NPI to test reproducibility was presented by BinHimd and Coolen,6,18 who
explored NPI reproducibility for simple nonparametric tests, such as the Wilcoxon Mann-Whitney test,
and they also developed NPI bootstrap, which is a computational implementation of NPI that is also
employed in this paper. Alqifari and Coolen19,20 developed NPI reproducibility for tests on population
quantiles and for a precedence test. Marques et al.21 study reproducibility for likelihood ratio tests. NPI
reproducibility has not yet been presented for the t-test, which is a common test used in pharmaceutical
research. Moreover, to date NPI exploration has been mainly theoretical. This paper contributes to the
literature by presenting NPI reproducibility for the t-test and its application in a real-world scenario.
The paper begins with a brief review of nonparametric predictive inference NPI and NPI bootstrap in
Section 2. Section 3 presents an algorithm for calculating the reproducibility of the t-test for comparison
of two groups (Algorithm 1), and we present the results of simulation studies to investigate the
reproducibility of the t-test. Following the simulation study, a pre-existing pharmaceutical test scenario
is introduced and the reproducibility of pairwise comparisons tests for this scenario is studied in Section
Prepared using sagej.cls
4 Statistical Methods in Medical Research XX(X)
4. This test scenario investigates the optimal dose of a drug. Different doses of the treatment are given
to members of different groups and pairwise comparisons are carried out on a recorded variable between
adjacent doses. In Sections 3 and 4 we explore the relationship between two test statistics, namely
Cohen’s d and the p-value, and NPI reproducibility. We explore the assumption that, if the original test
statistic is close to the threshold value between rejection of the null hypothesis and non-rejection, then the
test can be expected to be less reproducible than when the test statistic is further away from the threshold.
We also briefly compare reproducibility of the t-test and the Wilcoxon Mann-Whitney test.
Finally, a novel algorithm for calculating the reproducibility of the final decision based on multiple
pairwise t-tests (Algorithm 2) is described and applied to the pharmaceutical test scenario in Section
5. This final decision is of interest as in practice decisions are often based on more than one single
statistical test; hence studying its reproducibility is important and to date has received little attention
in the literature. The paper concludes with a summary of the findings and with formulation of future
research topics in Section 6. All calculations have been done using R version 3.2.4, the code is available
from the link https://tahanimaturi.com/rcodes/Rcodes-SMMR-May-2021.zip.
2 Nonparametric predictive inference and bootstrap
Nonparametric predictive inference (NPI) is based on Hill’s assumption A(n), which is a post-data
assumption that gives conditional probabilities for a future observation.22 Let X1, . . . , Xn, Xn+1 be
real-valued exchangeable random quantities. We observe X1, . . . , Xn and aim to predict Xn+1 based on
those n observations. The ordered observed values are x(1) < x(2) < ... < x(n) and let x(0) = −∞ and
x(n+1) =∞, or use known or assumed bounds for the support of the random quantities, say x(0) = L
and x(n+1) = R.16 Then for the future observation Xn+1, based on n observations, the assumption A(n)
is16:
P (Xn+1 ∈ (x(j−1), x(j))) =
1
n+ 1
, for j = 1, 2, ..., n+ 1. (1)
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This means that Xn+1 is equally likely to be in any of the intervals created by the ordered observed
data. Note that under A(n) it is assumed that there are no ties. Methods for dealing with ties in general
nonparametric statistical methods are presented by Gibbons and Chakraborti.23 In the NPI framework,
ties can be dealt with by breaking them by a very small amount.24–26
The NPI approach can also be used for multiple future observations via the consecutive application
of Hill’s assumption A(n), A(n+1), . . . , A(n+m−1), which together are denoted by A(·).20 An ordering






possible orderings of n data observations and m future observations, and under A(·)
all these orderings are equally likely.20,27 Let Sij denote the number of future observations in the interval





and j = 1, ..., n+ 1. Here
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Any specific ordering only specifies the number of future observations in each interval Ij , no
assumptions are made about where exactly in Ij the future observations will be. In general, uncertainty
is often expressed using lower and upper probabilities in the NPI framework. The lower probability for
an event E is the proportion of orderings Oi for which event E is necessarily true, while the upper
probability for E is the proportion of orderings Oi for which E can hold.20
In this paper, however, we do not compute lower and upper reproducibility probabilities for the t-test
for two reasons: First, it is computationally hard to derive such lower and upper probabilities for practical
data sets since the number of orderings to consider grows exponentially as the number of the original data
points increases. Secondly, computing the minimum and maximum values of the t-test statistic for m
future observations with given ordering Oi is difficult, because this statistic depends both on the sample
mean and variance. Instead, we use NPI bootstrap (NPI-B), which, rather than calculating lower and
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upper probabilities, tends to provide a value in between which serves well as an indication of the test
reproducibility.28 NPI-B is based on A(·) and it follows the concept of all orderings Oi being equally
likely.28 NPI-B differs from Efron’s bootstrap,29 mainly as it is developed for prediction, for which it is
important that future observations are not restricted to already observed values, while Efron’s bootstrap
is aimed at estimating of population characteristics.18,28
In the NPI-B method, there are n data observations and interest is in m future observations. Let N
denote the number of bootstrap samples. The NPI-B method is as follows:
1. Create n+ 1 intervals from n ordered observations.
2. Sample an interval with equal probability.
3. From that interval, sample uniformly a value and then add it to the data set.
4. In total sample m further values in the same way to form an NPI-B sample.
5. Create in total N NPI-B samples.
Note that, in this paper, bounded ranges [L,R] for the random quantities are assumed for NPI-B.
It is possible to generalize this to sampling from the real-line,18 but it does not make a substantial
difference to the reproducibility of the considered tests and it can greatly increase computation time.
We determine the bounds L and R, based on the sample, as follows: L = x(1) −maxi(x(i) − x(i−1))
and R = x(n) +maxi(x(i) − x(i−1)), where i = 2, 3, ..., n.
3 NPI reproducibility for pairwise t-test
The NPI reproducibility probability is the probability for the event that, if a test were repeated under
identical circumstances and with the same sample size, the same test outcome would be reached. The
NPI reproducibility probability does not imply anything about getting the test outcome “right”; for that,
traditional aspects of hypothesis testing, such as level significance, power and other related post-data
metrics, are relevant. This section studies reproducibility for the Student’s t-test for comparison of two
groups from the NPI perspective. First, we introduce an algorithm for calculating NPI reproducibility
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Algorithm 1 Calculating NPI-B-RP for the t-test for comparison of two groups
1: Apply the t-test on the two original samples, x and y, and record the test outcome: t∗ = 1 if H0 is
rejected and t∗ = 0 if H0 is not rejected.
2: Draw an NPI-B sample of size nx from sample x and an N NPI-B sample of size ny from sample y.
Apply the t-test to these two bootstrapped samples.
3: In total perform Step 2 N times for j = 1, ..., N and each time record the test outcome: tBj = 1 if
H0 is rejected and tBj = 0 if H0 is not rejected.




5: Perform Steps 2-4 h times, denote the resulting values rp by rp1, rp2, ..., rph.
for the t-test for comparison of two groups of data (Algorithm 1). Secondly, the NPI reproducibility
is explored though simulations in Section 3.2. Within the simulations, relationships between the
reproducibility probability and statistics of the original data (the p-value and Cohen’s d estimate) are
studied. As a nonparametric counterpart to the t-test, the Wilcoxon Mann-Whitney test (WMT) can be
performed to compare two groups in cases where the normality assumption may not be reasonable. Thus,
we briefly investigate reproducibility of the WMT and compare it to reproducibility of the t-test in Section
3.3.
3.1 Algorithm for NPI reproducibility for pairwise t-test
Algorithm 1 uses NPI bootstrap to derive the reproducibility probability for the t-test, indicated by NPI-
B-RP. As these values result from the use of the NPI bootstrap methods, the are effectively estimates.
The inputs into Algorithm 1 are the two original samples, x and y, their corresponding sample sizes nx
and ny , the number of runs h and the number of bootstrapped samples per run N . We apply Algorithm 1
with N = 1000 and h = 100.
The algorithm for calculating NPI-B-RP for the t-test has been adopted from the NPI-B-RP for
the Wilcoxon Mann-Whitney test (WMT), which was presented in BinHimd’s thesis,18 who briefly
investigated NPI reproducibility for the WMT.
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3.2 Simulations
In this section, we study the reproducibility probability (NPI-B-RP) for the t-test via simulations,
where we calculate the reproducibility using Algorithm 1. The null hypothesis is H0 : µx = µy and the
alternative hypothesis isH1 : µx > µy , the level of significance is α = 0.05. We simulate data both under
H0 and under H1. Under H0 we generate data from the normal distribution with mean 0 and standard
deviation 1 for both groups. Under H1 we generate data from two normal distributions with different
means, µx = 1 and µy = 0, but both with standard deviation 1. Further simulations were performed for
different values of the means and standard deviations under H1, these all led to similar results as for the
case presented here.
The inputs for the simulation study are as follows: the sample size n = 6, 10, 20; means µ1, µ2
and standard deviations σx and σy are as given in the previous paragraph; and the number of runs
per simulation N = 200. For each run, one sample of size n is generated from each of these normal
distributions, the t-test is performed on these two samples and the p-value is computed, and NPI-B-RP
for the t-test is calculated using Algorithm 1. We also consider Cohen’s d for the tests; this is an often





where s is the pooled sample standard deviation. As two simulated samples in pairwise tests in this paper
are always of the same size, and the samples in the pharmaceutical scenario in Section 4 are nearly of the
same size while their standard deviations are similar, we just use as pooled sample standard deviation the
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First, we examine the relationship between NPI-B-RP and the p-value for the t-test in the simulations.
Figure 1 (simulations under H0) and Figure 2 (simulations under H1) display plots of these metrics for
the three different sample sizes, with separate plots for the rejection cases only (p-value less than 0.05). It
is clear that, as expected, reproducibility is the lowest close to the test threshold, so if the p-value is close
to α = 0.05, In such cases, NPI-B-RP tends to be lower in case of rejection (red cases in the figures)
than for non-rejection (blue cases). Low values of NPI-B-RP are worrying from a practical perspective,
in particular in case H0 is rejected with the p-value only just below the level of significance, because
many experiments are explicitly designed with the aim to find evidence supporting H1. NPI-B-RP tends
to increase when the p-value moves away from α = 0.05, which is also as expected. Similar patterns have
been seen in applications of NPI reproducibility for several other test scenarios.6,21 For the simulations
under H1, increasing n leads to fewer cases with larger p-values, which simply results from the test
becoming more powerful for larger n. As a consequence, reproducibility for most non-rejection cases for
larger n becomes relatively lower compared to non-rejection cases for small n, when data are sampled
under H1.
Secondly, we explore the relationship between NPI-B-RP and Cohen’s d. Figure 3 shows the plots of
these two metrics for simulations under H0 and H1. In Figure 3 there is a V-shaped pattern: both for the
rejection cases (right side of the V-shape, in red) and the non-rejection cases (left side of the V-shape,
in blue), the NPI reproducibility of the t-test tends to increase when Cohen’s d moves away from the
area where the V-shape has the lowest point. The patterns are similar across the different distribution
parameters and sample sizes, where the range of the values of Cohen’s d becomes a bit smaller for larger
sample sizes due to the reduced variability of the sample means.
Finally, we study variability of NPI-B-RP by applying Algorithm 1 several times for the same two
datasets. The resulting outputs varied very little among the different applications, with the means of the
values rp1, . . . , rp100 differing only in the third decimal. As this mean of the rp-values can be considered
to best present the NPI reproducibility of the test, this rather minimal variability suggests that the choices
N = 1000 and h = 100 are appropriate to ensure that our inferences are accurate.
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3.3 NPI reproducibility for Wilcoxon Mann-Whitney test
It is of interest to compare NPI-B-RP for the t-test with NPI-B-RP for the Wilcoxon Mann-Whitney test
(WMT),31 an often used nonparametric counterpart to the t-test. This is straightforward by replacing the
t-test by the WMT in Algorithm 1. Figure 4 shows plots for the NPI-B-RP for the WMT and the p-values
for the WMT for simulations under H1. These show a similar relationship between the reproducibility
probability and the p-value as for the t-test in Figure 2, with however fewer different p-values being
possible due to the WMT being based on the ranks. Comparison of the reproducibility of these two tests
with simulated data under H0 also led to very similar results, these are not reported here.
4 NPI reproducibility for t-test applied to a pharmaceutical test scenario
This section presents the application of NPI-B-RP for the pairwise t-tests, as presented in Section 3,
to a pre-existing dataset from an internal preclinical study assessing the optimal dose of a drug. No
new experiments were carried out and the original statistical analysis framework for the experiment was
adopted. Section 4.1 introduces the motivating pharmaceutical test scenario. NPI reproducibility for the
pairwise comparisons in this scenario is presented in Section 4.2.
4.1 Pharmaceutical test scenario
The experiment assesses 6 concentrations of a drug; A is the control group and B-F are groups given
increasing concentrations of the drug. For each group, there is one measurement available for each
individual. The measurement is such that the lower the recorded value is, the better the drug performs at
that concentration. The data has been log transformed to meet the t-test assumption of normality; they
are presented in Table 1 and Figure 5.
Five pairwise comparisons are carried out between adjacent concentrations of the drug (A vs. B, B
vs. C, C vs. D, D vs. E, E vs. F). For each pairwise comparison, the question of interest is if the dose
with higher concentration is performing better than the dose with lower concentration. In each pairwise
comparison, the upper-sided equal variance t-test is applied. Let µH denote the population mean for the
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Dose
A B C D E F D’
0.7450 0.5148 0.1088 0.0133 -0.1221 -0.1946 0.4033
0.7513 0.5280 0.1732 0.0265 -0.1010 -0.0520 0.4087
0.8484 0.5546 0.1896 0.0302 -0.0519 -0.0417 0.4103
0.8584 0.5553 0.2202 0.0444 -0.0436 -0.0039 0.4163
0.8728 0.6265 0.2352 0.0882 -0.0200 0.0076 0.4354
0.8964 0.6315 0.2697 0.1461 -0.0182 0.0196 0.4624
0.9053 0.6890 0.3298 0.1545 -0.0104 0.0512 0.4665
1.0981 0.7605 0.4150 0.1585 0.0879 0.1540 0.4684
0.7843 0.4234 0.2638 0.1390 0.2247 0.5232
0.8173 0.4401 0.1945
Table 1. Log transformed data for each dose (D’ replaces D in Section 5.2).
dose with higher concentration and µL the population mean for the dose with lower concentration. The
null hypothesis is H0 : µL = µH and the alternative hypothesis is H1 : µL > µH . The significance level
α is equal to 0.05. For each pairwise comparison, the test outcome is either to reject (Y) or to not reject
(N) the null hypothesis.
The results of multiple pairwise comparisons for the data presented in Table 1 are YYYYN, indicating
that the null hypotheses are rejected for all pairwise comparisons except for last one, E vs. F. As seen in
Figure 5, as the dose increases, the measurements tend to decrease until dose E.
Note that the Wilcoxon Mann-Whitney test leads to the same test outcomes for all these pairwise
comparisons.
4.2 NPI reproducibility for the pairwise tests for the pharmaceutical test scenario
In this section, the Algorithm 1 (from Section 3) is applied to the test scenario described in Section 4.1
and conclusions regarding reproducibility are drawn. The Algorithm 1 outputs and the statistics of the
original test for all pairwise comparisons are presented in Table 2. We consider the mean value of the
outputs as the best indication of NPI reproducibility, we also refer to this mean as the NPI-B-RP value.
First, we consider what conclusions about NPI-B-RP can be directly made from the pharmaceutical
test scenario. The pairwise comparison E vs. F has high NPI-B-RP value, 0.911. This means that if the
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test were repeated under identical circumstances and with same sample sizes, then the same test outcome
would be reached with estimated probability 0.911. By comparison, the NPI-B-RP value for the pairwise
comparison D vs. E is 0.586. It is up to the decision makers to consider the NPI-B-RP values alongside
other statistical information and inferences, such as the effect size and power, in order to decide on the
trustworthiness of the test results.
Secondly, we explore how the NPI reproducibility values relate to statistics of the t-test applied to the
original data, these statistics are also displayed in Table 2. Note that these tests are pairwise comparisons
where we do not yet take into account that multiple tests are performed simultaneously. Effect Size is the
difference between the respective sample means; as Cohen’s d is closely related to it, and the relationships
between NPI-B-RP for the t-test and either the Effect Size or Cohen’s d are very similar; thus, we only
consider Cohen’s d in the following discussion. Figure 6 illustrates the relationship between NPI-B-RP
for the t-test, indicating the minimum, mean and maximum values of the NPI-B-RP output of Algorithm
1, for each of the pairwise comparisons, and the p-values and Cohen’s d. There are some clear patterns:
For example, NPI-B-RP is smallest for the pairwise comparison D vs. E, where the p-value is closest
to the threshold value 0.05 and Cohen’s d is small. A further observation is that high NPI-B-RP values
are obtained for several of the pairwise comparisons, both for some cases where the null hypothesis
is rejected, in particular for the comparison B vs. C, and for the comparison E vs. F where the null
hypothesis is not rejected. For B vs. C, the p-value is very small compared to α = 0.05 and Cohen’s d
is very large, as Cohen’s d greater than 0.8 is typically considered to be large.30 For E vs. F, the p-value
Statistics of the original data Algorithm 1 output
Pair Reject? p-value Effect Size Cohen’s d t-test WMT
min mean max min mean max
A vs. B Yes 0.0003 0.226 2.041 0.917 0.937 0.954 0.882 0.902 0.927
B vs. C Yes 0.0000 0.366 3.213 0.999 1.000 1.000 0.999 1.000 1.000
C vs. D Yes 0.0007 0.178 1.753 0.841 0.880 0.904 0.821 0.862 0.890
D vs. E Yes 0.0191 0.097 1.038 0.552 0.586 0.622 0.566 0.606 0.642
E vs. F No 0.5977 -0.013 -0.115 0.885 0.911 0.928 0.917 0.935 0.958
Table 2. Statistical and reproducibility analysis for the pairwise comparisons
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is very large compared to α = 0.05 and Cohen’s d is negative. We conclude that our observations about
NPI-B-RP for the pharmaceutical test scenario are consistent with the observations made in Section 3.2.
The key observations are: NPI-B-RP is low when the p-value is close to the level of significance α. For
non-rejection cases, even when the p-value is much greater than α, NPI-B-RP stays a bit below 1.
Finally, we compare NPI-B-RP for the t-test and for the WMT (Figure 7). The NPI-B-RP values for
both tests for this case study are quite similar. This may be due to the fact that the log-transformed
data used can reasonably be assumed to be normally distributed. This conclusion also agrees with the
conclusions from the simulation study (Section 3.3).
5 Reproducibility of the final decision based on multiple pairwise
comparisons
In Section 3 we introduced NPI-B-RP for the t-test for the comparison of two groups and in Section
4 we presented NPI-B-RP for pairwise comparisons in a pharmaceutical test scenario. However, in this
test scenario, the final choice of a particular dose is based on the multiple pairwise comparisons. This
section explores the NPI-B-RP of this final decision and presents a general algorithm for calculating such
reproducibility.
In a case involving multiple pairwise comparison tests, it is important to consider how the final decision
is made, and which dose is finally selected. We consider the scenario that the decision maker selects the
smallest dose for which, in the pairwise comparisons above, the null hypothesis of no difference between
the results for this dose and the next larger dose, is not rejected. In the presented test scenario, this leads
to dose E being chosen, and only the actual outcomes of the five pairwise tests, which we can present as
YYYYN, leads to this final decision.
In Section 5.1 we present the general algorithm for calculating reproducibility of the final decision,
and we apply this algorithm to the test scenario from Section 4.1. In Section 5.2 we modify the data from
the test scenario in order to illustrate and explore reproducibility of the final decision.
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Algorithm 2 Calculating NPI reproducibility of the final decision
1: For each group Gi, i = 1, . . . , g, generate an NPI-B sample.
2: Apply the multiple pairwise analysis to the bootstrapped g data sets. This includes the p-value
adjustment using the BH method.
3: Record the (g − 1) test outcomes. For example, test outcomes YYYYN mean do not reject H0 only
for the last pairwise comparison.
4: In total perform Steps 1-3 N times.
5: Create a frequency table of all the possible combinations of test outcomes recorded in Step 4.
6: Calculate RPD, the proportion of combinations in Step 5 that lead to the same final decision as the
original tests.
5.1 Algorithm for NPI reproducibility for the final decision
Algorithm 2 presents a step-by-step general method for calculating NPI-B-RP of the final decision.
The number of groups in the multiple pairwise comparison is denoted by g. Similarly to Algorithm
1, Algorithm 2 uses NPI bootstrap with finite intervals, as introduced in Section 2. So for each group,
Gi, i = 1, ..., g, finite end points for the range of the possible values need to be selected. The sample
sizes of the bootstrap samples are the same as of the original data. The reproducibility for the final
decision, denoted by RPD, is defined as the proportion of all the combined g − 1 test outcomes leading
to the same final decision as the original tests. In order to account for the fact that the five tests are run
simultaneously, the p-values are adjusted for multiple testing using the Benjamini and Hochberg (BH)
procedure32 to control the false discovery rate. The adjusted p-values for each pairwise comparison are
A vs. B: 0.0007; B vs. C: 2.7× 106; C vs. D: 0.0012; D vs. E: 0.0239; E vs. F: 0.5977. This procedure
strives to decrease the proportion of false positives. In the test scenario, after the p-value adjustment, the
test decision outcomes are still YYYYN.
We apply Algorithm 2 to the pharmaceutical test scenario from Section 4.1 with g = 6 groups. We set
N = 1000 and the final decision is based on the test results YYYYN, and so dose E is chosen because
there is no significant indication that dose F is better than dose E. Algorithm 2 leads to two different types
of outcome: A frequency table (Step 5) which provides all the combinations of test outcomes reached in
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N runs of Step 1-3, and the value of RPD (Step 6), which is the proportion of all combinations of test
outcomes that lead to the original test decision.
For this particular dataset and final decision rule, the RPD for an identical final decision (Step 6
of Algorithm 2) is 0.400, which is a relatively low value compared to the NPI-B-RP values for the
pairwise comparisons as derived in Section 4.2. A more nuanced way of exploring the Algorithm 2
outputs is obtained by considering a reproducibility tree, which shows all possible combinations of the
g − 1 test outcomes occurring in the frequency table. For the data set given in Table 1, there are 32
possible combinations of the 5 test outcomes. Not all combinations of test outcomes are generated by
Algorithm 2 on this dataset. Table 3 presents all the combinations of test outcomes and their frequencies.
Figure 8 shows the reproducibility tree for the test scenario. The top node represents the 1000 runs of
Steps 1-3 in Algorithm 2. This node splits into two nodes: Y...., all possible test outcomes where in
the first pairwise comparison the null hypothesis was rejected, each dot represents a following pairwise
comparison with any possible test outcome; and N...., all combinations of tests outcomes where in the
first pairwise comparison the null hypothesis was not rejected. These branches again split, each into two,
depending on the conclusion of the second pairwise comparison. For example, YY... means that the first














Table 3. Frequency table (Step 5 of Algorithm 2)
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and second pairwise comparisons lead to rejection of the respective null hypothesis. The same pattern is
followed up to the last pairwise comparison.
The most frequent output is YYYYN, which is the same as the original test results and leads to dose E
being chosen. The branch leading to this final decision is highlighted. The second most frequent output is
YYYNN, leading to dose D. The fact that YYYNN is the second most frequent output can be explained
by the relatively small NPI-B-RP value for the pairwise comparison between doses D and E.
We repeated Algorithm 2, with N = 1000, ten times for this scenario. The resulting reproducibility
trees were the same, only the numbers differed slightly, theRPD values, so the proportion of runs leading
to the same output YYYYN, were: 0.370, 0.376, 0.388, 0.400, 0.402, 0.403, 0.410, 0.412, 0.415, 0.424.
By comparison, the NPI-B-RP values calculated on different separate runs of Algorithm 1 differ in the
third decimal. Although small, the variability in these reproducibility probabilities is larger than for the
individual pairwise comparisons, this is due to the use of multiple pairwise comparisons to determine the
reproducibility of the final decision.
5.2 Further illustration of reproducibility of the final decision
If we follow the final decision rule for the test scenario data, only one combination of the pairwise test
results, namely YYYYN, leads to the choice of dose E. To better illustrate the concept of reproducibility
of the final decision, we change the data for dose D by adding 1.5 to all the data points before they are log
transformed, the resulting values are denoted by D’ in Table 1 and Figure 5. This leads to the pairwise
test outcomes YYNYN, and the final decision would be to choose dose C, since dose D does not do better
than dose C. To determine the reproducibility of the final decision, we again apply Algorithm 2 to the test
scenario with these modified data (Figure 9). Now there are 4 combinations of test outcomes that lead to
the same final decision to choose dose C: YYNYN (the original test outcome), YYNYY, YYNNY and
YYNNN. The reproducibility of the final decision is derived as the proportion of all simulation runs in
which one of these 4 combinations of test outcomes occurs. As the combinations YYNNY and YYNNN
did not occur, the reproducibility of the final decision for the modified data is derived by summing the
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proportions of runs with outcomes YYNYY and YYNYN, leading to 0.910, as highlighted in Figure
9. This simulation was also repeated ten times, and the results were very similar, with RPD values
0.894, 0.910, 0.911, 0.917, 0.917, 0.917, 0.919, 0.919, 0.919, 0.922. In all these simulations, the resulting
reproducibility trees were the same, with only small differences in the numbers.
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(f) n = 20, rejections
Figure 1. Simulations under H0: values of NPI-B-RP (minimal, mean and maximal) for the t-test vs p-value
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(f) n = 20, rejections
Figure 2. Simulations under H1: values of NPI-B-RP (minimal, mean and maximal) for the t-test vs p-value
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(f) Under H1, n = 20
Figure 3. Simulations under H0 and H1: values of NPI-B-RP (minimal, mean and maximal) for the t-test vs
Cohen’s d
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(f) n = 20, rejections
Figure 4. Simulations under H1: values of NPI-B-RP (minimal, mean and maximal) for the WMT vs p-value
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Figure 5. Log transformed data for each dose and outcomes of the pairwise comparisons (D’ only used in
Section 5.2)
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(b) NPI-B-RP versus Cohen’s d































































































Andrea Simkus, Frank P.A. Coolen, Tahani Coolen-Maturi, Natasha A. Karp and Claus Bendtsen 25
Figure 9. Illustration of the final decision rule: Tree diagram for reproducibility of the final decision for the



















NPI reproducibility provides an inference method for the probability for the event that, if a test
were repeated under identical circumstances and with the same sample size, the same test outcome
would be reached. This paper contributes to the development of NPI reproducibility by exploring
the reproducibility for the two-sample Student’s t-test, which is widely used in practice. First, the
reproducibility for the t-test has been studied via simulations, followed by application to such tests in
a pharmaceutical scenario. Secondly, reproducibility for a final decision based on multiple pairwise t-
tests has been investigated.
We explored the reproducibility of the pairwise t-test and investigated the relationships between
NPI reproducibility and two common test statistics, the p-value and the Cohen’s d. As the p-value
approaches the significance level α, the NPI reproducibility decreases, and for p-values close to α the
NPI reproducibility is typically lower in case of rejection of the null-hypothesis than for non-rejection.
This relation also held when we compared the reproducibility and Cohen’s d, and further simulations,
beyond the cases presented in this paper and with other input parameters, led to similar results. We also
compared reproducibility of the t-test and the Wilcoxon-Mann-Whitney test in our simulations and for
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the pharmaceutical test scenario, the results were quite similar. This might be due to the fact that the
considered data could, after transformation, reasonably be assumed to come from a normally distributed
population, and the data in the simulation study were generated from normal distributions. More detailed
investigation of differences in reproducibilities of these two tests, for example for data from skewed
distributions, is a topic for future research.
The NPI reproducibility for the pairwise t-tests can provide useful insights for practical applications.
For example, in the pharmaceutical test scenario one of the pairwise comparisons had low reproducibility,
so it might be advisable to explore the comparison of those two groups in more detail, possibly by
additional experiments. NPI reproducibility can be used in conjunction with other test statistics, such as
the p-value and the Cohen’s d, to support the decision process based on the data and tests. Such use of
NPI reproducibility in practical decision making is left as an important topic for future research.
In the pharmaceutical scenario considered in this paper, multiple comparisons are performed and their
test results lead to a final decision on an appropriate dose. It is therefore also important to consider the
reproducibility of this final decision; and one could say that this is the most important outcome of the
combined hypothesis tests. We introduced an algorithm for deriving the NPI reproducibility of this final
decision, this has not previously been considered in the literature. For the presented pharmaceutical test
scenario, the reproducibility of the final decision is smaller than the reproducibilities for all the pairwise
comparisons on which the final decision is based. This is a logical consequence of using multiple pairwise
comparisons to reach the final decision. Low reproducibility of the final decision should be taken into
account by decision makers, investigating possible further actions to improve this situation is also left for
future research.
Related to this paper, there are many more topics for future research. The study of the sensitivity
of the reproducibility calculations to the choice of the left and the right bound of the support of the
finite bootstrap could be investigated. The reproducibility in this paper is expressed with the use of
precise probabilities, whereas classical NPI uses the more general concept of imprecise probability to
quantify uncertainty, hence leading to lower and upper reproducibility probabilities. Deriving NPI lower
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and upper probabilities for the t-test is an interesting topic for further research. Coolen and Marques33
carried out research on determining estimates for NPI-RP through sampling of orderings for likelihood
test; this method could be explored for the tests in this paper if the NPI lower and upper reproducibility
probabilities can be computed or approximated. The main challenge is to apply NPI reproducibility to
many real-world test scenarios and to use it as input into actual decision processes. Follow-up actions
in case of low reproducibility are also important and research into this has not yet been reported in the
literature.
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